Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Somavert Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Somavert (pegvisomant) Coverage for Acromegaly

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Somavert (pegvisomant) used to treat acromegaly under UnitedHealthcare pharmacy benefits, subject to member-specific benefit terms and applicable regulatory requirements.

    Policy Summary
    PayerUnitedHealthcare
    PolicySomavert (pegvisomant) Coverage for Acromegaly
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of acromegaly and either an inadequate response to surgery or radiation therapy, or documentation that the member is not a candidate for both treatments.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    1Covered medication
    AcromegalyCovered indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Positive clinical response
    Reauthorization requirement

    Therapy Coverage Criteria

    Initial therapy

    Covered when all of the following are met:

    Initial authorization

    • Diagnosis of acromegaly.
    • Prior treatment or candidacy

      • Inadequate response

        • Treatment failure: Inadequate response to surgery.
        • Treatment failure: Inadequate response to radiation therapy.
      • Not a candidate

        • Treatment not appropriate: Not a candidate for surgery.
        • Treatment not appropriate: Not a candidate for radiation therapy.

    Continuation therapy

    Covered when the following criterion is met:

    Reauthorization: Documentation of positive clinical response to Somavert therapy.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required. Somavert may be initially approved when the member has acromegaly and meets one qualifying prior-treatment condition.

    • Diagnosis of acromegaly
    • Inadequate response to surgery or radiation therapy, or not a candidate for surgery or radiation therapy
    • Initial authorization is issued for 12 months
    Prior Authorization

    Reauthorization Requires Positive Response

    Reauthorization requires documentation of a positive clinical response to Somavert therapy. When this criterion is met, authorization is issued for 12 months.

    • Documentation of positive clinical response to Somavert therapy
    • Reauthorization duration: 12 months

    Clinical Background

    Somavert (pegvisomant) is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The treatment goal is to normalize serum insulin-like growth factor-I (IGF-I) levels.

    Key Definition

    Acromegaly
    ConditionAcromegaly
    Treatment contextTreated with Somavert when there has been an inadequate response to surgery or radiation therapy, or when these therapies are not appropriate.
    Treatment goalNormalize serum insulinlike growth factor-I (IGF-I) levels.

    Somavert Initial Authorization Criteria

    Somavert initial authorization

    Initial therapy is covered when all of the following are met:

    Initial coverage

    • Diagnosis of acromegaly.
    • Treatment history or eligibility

      • Inadequate response

        • Treatment failure: Inadequate response to surgery.
        • Treatment failure: Inadequate response to radiation therapy.
      • Not a candidate

    Somavert Reauthorization Criteria

    Somavert reauthorization

    Reauthorization is covered when the following criterion is met:

    Clinical response: Documentation of positive clinical response to Somavert therapy.

    Authorization will be issued for 12 months.

    Policy Summary
    PayerUnitedHealthcare
    PolicySomavert (pegvisomant) Coverage for Acromegaly
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of acromegaly and either an inadequate response to surgery or radiation therapy, or documentation that the member is not a candidate for both treatments.
    SourceLink
    On This Page
    Therapy Coverage CriteriaAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionSomavert Initial Authorization CriteriaSomavert Reauthorization Criteria
    Documentation Required

    Initial Clinical Documentation

    Submit clinical documentation supporting the diagnosis and the qualifying prior-treatment history or treatment ineligibility before initial authorization can be approved.

    • Document a diagnosis of acromegaly
    • Document inadequate response to surgery or radiation therapy, or that the member is not a candidate for either treatment
    Documentation Required

    Continuation Response Documentation

    For reauthorization, submit clinical documentation demonstrating that the member has experienced a positive clinical response to Somavert therapy.

    • Document the member's positive clinical response to Somavert
    • Include response documentation with the reauthorization request
    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied when the required diagnosis or qualifying prior-treatment history is not established.

    • No documented diagnosis of acromegaly
    • No documented inadequate response to surgery or radiation therapy
    • No documentation that the member is not a candidate for surgery or radiation therapy
    Denial Risk

    Insufficient Response for Reauthorization

    Reauthorization may be denied when documentation does not demonstrate a positive clinical response to Somavert therapy.

    • Positive clinical response is not documented
    • Insufficient response documentation submitted with the reauthorization request
    • Treatment not appropriate: Not a candidate for surgery.
    • Treatment not appropriate: Not a candidate for radiation therapy.